Last reviewed · How we verify
NCT05016310
A Study of High-Dose Vit D Versus Standard of Care Vit D Supplementation
NA trial testing High Dose Vitamin D in Breast in 7 participants. Completed in 15 August 2024.
21 February 2024
Quick facts
| Lead sponsor | Wake Forest University Health Sciences |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 7 |
| Start date | 16 September 2021 |
| Primary completion | 21 February 2024 |
| Estimated completion | 15 August 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- High Dose Vitamin D — full drug profile →
- Standard of Care Vitamin D
Conditions studied
- Breast — all drugs for Breast →
- Breast Cancer — all drugs for Breast Cancer →
- Osteoporosis — all drugs for Osteoporosis →
Sponsor
Wake Forest University Health Sciences
Who can join
Adults 18 to 45, female only, with Breast or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized study evaluating the effects of early intensive vitamin D supplementation compared to standard of care vitamin D supplementation on bone health over an 18 month period.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05016310
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of High Dose Vitamin D
Trials testing the same drug.
- NCT04768439 — Low and High Doses of Prophylactic Vitamin D in Prevention of Osteopenia of Prematurity · Phase 2 · completed
Other recruiting trials for Breast
Currently open trials in the same condition.
- NCT07252986 — Clinical Translation Research on a Multi-omics Breast Cancer Distant Metastasis Prediction Model Empowered by Artificial · recruiting
- NCT06382272 — A Bionic Breast Project Using Neuroprosthesis to Reduce Chronic Pain After Mastectomy · NA · recruiting
- NCT06083415 — Early Breast Growth in Girls Aged 6 to 8 Years in the Current Environmental Context · NA · recruiting
- NCT04333706 — A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Hi · Phase 1, PHASE2 · recruiting
- NCT02734004 — A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. · Phase 1, PHASE2 · active not recruiting
Other Wake Forest University Health Sciences trials
Trials by the same sponsor.
- NCT07474090 — Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial · NA · not yet recruiting
- NCT07282444 — A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial · NA · not yet recruiting
- NCT06876896 — Intra-abdominal Pressure (IAP) During PFA Treatment of A-fib/ A-Flutter · NA · recruiting
- NCT07227051 — Optimizing Self-Monitoring Feedback Delivery for the Treatment of Overweight and Obesity · NA · recruiting
- NCT07215624 — Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05016310 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wake Forest University Health Sciences
- Last refreshed: 23 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05016310.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing